Elizabeth Guruceaga
Overview
Explore the profile of Elizabeth Guruceaga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Puyalto A, Rodriguez-Remirez M, Lopez I, Macaya I, Guruceaga E, Olmedo M, et al.
Mol Cancer
. 2024 Apr;
23(1):78.
PMID: 38643157
Background: The identification of novel therapeutic strategies to overcome resistance to the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge. This study analyzes the effects of...
2.
Nava D, Ausejo-Mauleon I, Laspidea V, Gonzalez-Huarriz M, Lacalle A, Casares N, et al.
Neuro Oncol
. 2024 Mar;
26(8):1509-1525.
PMID: 38554031
Background: Pediatric high-grade gliomas (pHGGs), including diffuse midline gliomas (DMGs), are aggressive pediatric tumors with one of the poorest prognoses. Delta-24-RGD and ONC201 have shown promising efficacy as single agents...
3.
Patino-Garcia A, Guruceaga E, Andueza M, Ocon M, Fodop Sokoudjou J, de Villalonga Zornoza N, et al.
EBioMedicine
. 2024 Mar;
102:105048.
PMID: 38484556
Background: Tobacco is the main risk factor for developing lung cancer. Yet, while some heavy smokers develop lung cancer at a young age, other heavy smokers never develop it, even...
4.
Macaya I, Roman M, Welch C, Entrialgo-Cadierno R, Salmon M, Santos A, et al.
Nat Commun
. 2023 Oct;
14(1):6332.
PMID: 37816716
Drug combinations are key to circumvent resistance mechanisms compromising response to single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context of KRAS-mutated...
5.
Ausejo-Mauleon I, Labiano S, Nava D, Laspidea V, Zalacain M, Marrodan L, et al.
Cancer Cell
. 2023 Oct;
41(11):1911-1926.e8.
PMID: 37802053
Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain stem tumor and the leading cause of pediatric cancer-related death. To date, these tumors remain incurable, underscoring the need for efficacious...
6.
Entrialgo-Cadierno R, Cueto-Urena C, Welch C, Feliu I, Macaya I, Vera L, et al.
Mol Cancer
. 2023 Jun;
22(1):97.
PMID: 37328838
No abstract available.
7.
Entrialgo-Cadierno R, Cueto-Urena C, Welch C, Feliu I, Macaya I, Vera L, et al.
Mol Cancer
. 2023 May;
22(1):86.
PMID: 37210549
Background: The discovery of functionally relevant KRAS effectors in lung and pancreatic ductal adenocarcinoma (LUAD and PDAC) may yield novel molecular targets or mechanisms amenable to inhibition strategies. Phospholipids availability...
8.
Erice O, Narayanan S, Feliu I, Entrialgo-Cadierno R, Malinova A, Vicentini C, et al.
Clin Cancer Res
. 2023 Jan;
29(6):1137-1154.
PMID: 36607777
Purpose: The identification of pancreatic ductal adenocarcinoma (PDAC) dysregulated genes may unveil novel molecular targets entering inhibitory strategies. Laminins are emerging as potential targets in PDAC given their role as...
9.
Larrea E, Fernandez-Rubio C, Pena-Guerrero J, Guruceaga E, Nguewa P
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36361992
Around 15% of cancer cases are attributable to infectious agents. Epidemiological studies suggest that an association between leishmaniasis and cancer does exist. Recently, the homologue of PES1 in (LmjPES) was...
10.
Reparaz D, Ruiz M, Silva L, Aparicio B, Egea J, Guruceaga E, et al.
Front Immunol
. 2022 Oct;
13:991311.
PMID: 36300124
Vaccination using optimized strategies may increase response rates to immune checkpoint inhibitors (ICI) in some tumors. To enhance vaccine potency and improve thus responses to ICI, we analyzed the gene...